05 Sep 2022 AVA6000 receives Orphan Drug Designation from the US Food and Drug Administration Investors | Therapeutics
01 Sep 2022 Phase I clinical study of AVA6000 to advance to the fourth cohort Investors | Therapeutics
29 Jun 2022 Avacta announces second dose escalation in the Phase I clinical study of AVA6000 Pro-doxorubicin Investors | Therapeutics
16 May 2022 AffyXell expands its strategic partnership with GenScript ProBio Investors | Therapeutics
11 May 2022 Avacta establishes new Therapeutics headquarters at Scale Space, Imperial College White City Campus Investors | Therapeutics
12 Apr 2022 Poster presented at the American Association for Cancer Research Annual Meeting available to download Investors | Therapeutics